Swiss National Bank Acquires 33,900 Shares of IQVIA Holdings Inc. $IQV

Swiss National Bank boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 7.3% in the first quarter, Holdings Channel.com reports. The institutional investor owned 499,780 shares of the medical research company’s stock after acquiring an additional 33,900 shares during the period. Swiss National Bank’s holdings in IQVIA were worth $85,232,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in IQV. J. Safra Sarasin Holding AG boosted its position in shares of IQVIA by 174.3% in the fourth quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock worth $2,891,000 after purchasing an additional 8,151 shares during the period. CWM LLC raised its position in shares of IQVIA by 23.9% during the 4th quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock valued at $12,585,000 after purchasing an additional 10,762 shares during the period. Franklin Street Advisors Inc. NC bought a new position in IQVIA in the 4th quarter worth $15,724,000. Calamos Advisors LLC increased its stake in IQVIA by 268.1% in the 4th quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after buying an additional 137,441 shares in the last quarter. Finally, HF Advisory Group LLC raised its holdings in IQVIA by 1,791.6% during the fourth quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company’s stock valued at $34,852,000 after acquiring an additional 146,444 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.9%

IQV stock opened at $204.33 on Tuesday. The firm has a fifty day moving average price of $185.66 and a 200 day moving average price of $187.72. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04. The firm has a market cap of $34.10 billion, a PE ratio of 25.32, a price-to-earnings-growth ratio of 1.85 and a beta of 1.20. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the business earned $2.70 earnings per share. IQVIA’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on IQV. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research note on Thursday, July 9th. Evercore reissued an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. HSBC reiterated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. Finally, Robert W. Baird boosted their target price on shares of IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $225.71.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.